The a platelet derived growth factor receptor (aPDGFR) extracellular Immunoglobulin (Ig) like domains 1 ± 3 contain major determinants for ligand interaction. We now report that a deletion of Ig-like loop 3, but not Iglike loop 1 or 2, of the aPDGFR causes ligandindependent transformation in NIH3T3 cells. Biochemical analyses of aPDGFR mutants lacking Ig-like loop 3 indicate that cellular transformation is mediated by ligand-independent activation of the aPDGFR tyrosine kinase activity as determined by receptor autophosphorylation both in vivo and in vitro. Moreover, crosslinking analysis of aPDGFR mutants expressed ectopically in NIH3T3 cells indicate that deletion within extracellular domain 3 leads to ligand-independent receptor dimerization. All of these ®ndings suggest that the Ig-like loop 3 of the aPDGFR contains the major determinants which inhibit receptor dimerization in the quiescent cells and that the ligand binding induces receptor activation by neutralizing the inhibitory eect of this domain.
Introduction
Platelet-derived growth factor (PDGF) is a potent mitogen involved in the normal proliferation and dierentiation of a variety of connective tissue cell types (Ross et al., 1986) . Abnormal expression of PDGF and its receptors may also contribute to a number of chronic diseases as well as cancer (Fleming et al., 1992) . The PDGF system is complicated in that three PDGF isoforms comprised of homo or heterodimers of A and B chains dierentially interact with a and b PDGF receptors (PDGFRs) encoded by two distinct genes (Claesson-Welsh et al., 1988; Matsui et al., 1989a; Yarden et al., 1986) . Moreover, there is accumulating evidence that PDGF activation involves recruitment of receptor dimers (Bishayee et al., 1989; Heidaran et al., 1991; Heldin et al., 1989; Seifert et al., 1989; Ueno et al., 1991) . In ®broblasts where both PDGFRs are expressed, PDGF-BB activates ab, bb and aa receptor dimers. PDGF-AA induces formation of only aa receptor homodimers, while PDGF-AB is capable of recruiting aa and ab dimers (Heidaran et al., 1991; Seifert et al., 1989) .
In previous studies, we have analysed PDGF binding properties utilizing an IL-3-dependent cell line, 32D, which is normally devoid of PDGF receptors. By expressing chimeric PDGFRs in this naive cell line, we have localized the binding domains of the aPDGFR. This region, which comprises the ®rst three immunoglobulin (Ig)-like loops of the ®ve external domains of the a or bPDGFR, when reciprocally exchanged, confers PDGF binding properties of the respective wild type receptor (Heidaran et al., 1990b) . Furthermore, it was also demonstrated that a deletion within the Ig-like loop 1 of the aPDGFR inhibits cell surface expression (Yu et al., 1994) . In contrast, the deletion within Ig-like loop 2 resulted in a marked decrease in its anity for PDGF-AA as compared to that shown for PDGF-BB . While the deletion within Ig-like loop 3 fully abolished the ligand/receptor interaction (Yu et al., 1994; Mahadevan et al., 1995) .
A number of other growth factor receptors have also been shown to dimerize in the presence of ligand. These include the human growth hormone receptor (Hurwitz et al., 1991) , the soluble extracellular domain of the epidermal growth factor receptor (de Vos et al., 1992) , and members of PDGFRs subfamily including CSF-1R and c-Kit (Heldin, 1995) . However, the molecular mechanism by which ligand binding stimulates formation of receptor dimers remains less de®ned. In the present report, we have investigated the oncogenic potential of a series of aPDGFR mutants in order to establish a working model for ligand-induced receptor dimerization and activation.
Results
Since alterations in the ligand-binding region of colony stimulating factor receptor (CSF-1R) has been documented to induce cellular transformation (Roussel et al., 1988) we initially sought to investigate the biological eects of dierential deletions within the ligand binding domain of the aPDGFR. NIH3T3 cells were transfected with expression vectors coding for wild type aPDGFR (aRWT) and several receptor mutants lacking the individual Ig-like loop 1, 2 and 3 of the aPDGFR designated aR D49 ± 100 , aR D150 ± 189 and aR D235 ± 290 , respectively. As shown in Figure 1 , transfection of the aRWT, aR D49 ± 100 and aR Figure 1f shows that foci induced by the aR D235 ± 290 expression vector were generally larger and more diuse than those induced by a v-sis/PDGF-B construct. Quantitative comparison of the transforming activities indicated that aR D235 ± 290 was around 10-fold less ecient than v-sis/PDGF-B, but was at least 100-fold more active than aRWT or aR D150 ± 189 at inducing focal transformation (Figure 2) .
To assess the malignant phenotype of NIH/aR D235 ± 290 cells, we next performed tumorigenicity studies in nude mice. As summarized in Figure 2 , NIH/aR
formed tumors in all inoculated mice. Similar results were obtained with v-sis transfectants. In contrast, marker-selected NIH3T3 cells transfected with the vector alone, aRWT or aR
, aR D150 ± 189 were not tumorigenic. Consistent with this result, the aR D235 ± 290 virus which was rescued by superinfection with the helper virus AP 129, induced focus formation with a high titer of around 10 4 u/ml, similar to that observed for the v-sis (data not shown).
Oncogenic activation of the aPDGFR is mediated by ligand-independent stimulation of receptor tyrosine kinase activity
Oncogenic activation of receptor tyrosine kinase often involves constitutive activation of receptor tyrosine kinase activity in conjunction with receptor overexpression. Therefore, we sought to examine the expression level of aPDGFRs and their autokinase activity. To compare the expression level of mutant aPDGFR, we utilized an anti-aPDGFR1 antibody generated against a peptide corresponding to amino acid residues 959 ± 973 of the human aPDGFR . As shown in Figure 3a , this antiserum detected two major protein species with molecular weights of 160 and 190 kDa corresponding to the immature and mature forms of human aRWT, respectively (Matsui et al., 1989a) . In addition, consistent with the predicted sizes of the deletion mutant, anti-aPDGFR1 detected similar levels of . Since the expression level of aR D235 ± 290 was comparable to that of the wild type aPDGFR, our data indicates that oncogenic activation of aR D235 ± 290 was not due to receptor overexpression.
To measure ligand-independent aPDGFR autophosphorylation activity, total lysates from each transfectants were ®rst immunoprecipitated using a monoclonal antibody (Mab-aR1) which recognizes the human but not the murine aPDGFR. The immune complexes were then subjected to immunoblot analysis using anti-aPDGFR1 or anti-phosphotyrosine (anti-PTyr). Figure 3b shows that comparable levels of the mature form of the aPDGFR could be readily detected in each immune complex. The aRWT was not tyrosine phosphorylated under these conditions. However, we unexpectedly observed that the aR D235 ± 290 was heavily phosphorylated on tyrosines in the quiescent cells (Figure 3c ). These ®ndings suggest that the deletion of Ig-like domain 3 leads to constitutive activation of receptor tyrosine kinase activity in vivo. To further investigate the role of Ig-like loop 3 in regulating the kinase activity of the aPDGFR, we next subjected the puri®ed human aPDGFR to an in vitro kinase assay. Results shown in Figure 3d indicate that deletion of Iglike loop 3 markedly increased the autokinase activity of the aPDGFR in vitro. Therefore, all of these ®ndings suggest that oncogenic activation of the aR D235 ± 290 involves ligand-independent activation of receptor autokinase activity.
To determine the eects of the deletion mutant on the ligand-dependent and independent tyrosine phosphorylation of a and bPDGFRs endogenously expressed in NIH3T3 cells (Heidaran et al., 1991; Seifert et al., 1989) , total cell lysates prepared from untreated or PDGF-BB treated NIH3T3 or NIH3T3/ aR D235 ± 290 cells were subjected to immunoblot analysis using anti-P-Tyr. Consistent with the size of the deletion mutant, a protein species with molecular weight of about 180 kDa was speci®cally phosphorylated on tyrosine in NIH3T3/aR D235 ± 290 (Figure 4a, lane  3) . Hence, we did not detect tyrosine phosphorylation of protein with a molecular size consistent with the size ) were treated with or without PDGF-BB (50 ng/ml) for 10 min at 378C. (a) Immunoblot analysis of total cell lysates with anti-P-Tyr. (b) soluble fractions (2 mg) were immunoprecipitated with Mab-aR1 which recognizes the human but not the murine aPDGFR. The immunecomplexes were electrophoretically separated, transferred to Immobilon-P (Millipore), and blotted with anti-P-Tyr of the endogenous a and bPDGFR under these conditions (Figure 4a lane 1 and 3) . Furthermore, PDGF-BB which binds both a and bPDGFRs, induced a similar level of tyrosine phosphorylation of the endogenous PDGFRs with molecular weights of around 190 kDa in NIH3T3 control cells or NIH3T3 cells transfected with the aR D235 ± 290 . To verify that the ligand-independent tyrosine phosphorylation detected in NIH3T3/aR D235 ± 290 was due to expression of the deletion mutant, total cell lysates were ®rst subjected to immunoprecipitation using anti-MabaR1 which recognizes the human but not the murine aPDGFR. The immune complexes were then electrophoretically separated and immunoblotted with anti-P-Tyr antibody. Results shown in Figure 4b indicate that the anti-MabaR1 could eciently immunoprecipitate the tyrosine phosphorylated species in NIH3T3/aR D235 ± 290 . In addition, Figure 4b shows that the level of tyrosine phosphorylation of the deletion mutant was not eected by PDGF treatment. This result is consistent with our previous data showing that aR D235 ± 290 fails to bind PDGF (Yu et al., 1994) . Thus, all of our ®ndings indicate that the aR D235 ± 290 deletion mutant undergoes ligand-independent tyrosine phosphorylation and that this eect does not cause the activation of coexpressed a and bPDGFRs.
Ligand-independent activation of aR D235 ± 290 is induced by receptor dimerization It is well documented that ligand binding can lead to receptor dimerization and activation. However, a temporal relationship between ligand binding, receptor dimerization and activation has not been clearly established. Since aR D235 ± 290 failed to bind PDGF, we next sought to investigate whether or not this mutant receptor might constitutively exist in the dimeric form. NIH3T3 cells transfected with the LTR2 vector alone, aRWT or aR D235 ± 290 were subjected to cross-linking analysis using BS 3 as a cross-linker. PDGF treatment induced stable PDGF receptor dimers in NIH3T3 transfectants ( Figure 5, lane 4) . While there was no detectable receptor dimerization in NIH3T3 transfected with aRWT prior to ligand stimulation, the presence of ligand-independent dimers was readily observed in NIH3T3 cells transfected with aR Deletion of Ig-like loop 3 induces formation of receptor dimers in vivo. Quiescent NIH3T3 cells were incubated with or without PDGF-AA (100 ng/ml) as described in Materials and methods in the presence (+) or absence (7) of BS 3 for 10 min at 378C. Cells were then lysed, and soluble fractions were immunoprecipitated with anti-P-Tyr. Immunoprecipitates were electrophoretically separated on a 4% SDS ± PAGE, transferred to Immobilon-P, and immunoblotted with anti-aPDGFR. The positions of receptor monomers (M) and dimers (D) are designated. Similar results were obtained in two other independent experiments Figure 6 Schematic representation of the proposed mechanism of PDGFR activation by PDGF. The immunoglobulin-like domains 1 ± 5 are represented by open geometrical shapes. The PDGF dimer is depicted by shaded boxes. Activation of PDGFR tyrosine kinase activity is denoted by changes in the shape of tyrosine kinase domain from rectangle into an oval shape. The putative dimerization domain is denoted by thick black line. (7) represents negatively charged species within Ig-like loop 3
Discussion
Constitutive activation of receptor tyrosine kinases can be achieved by several independent mechanisms. For example, deletion or mutation within the extracellular ligand-binding domains of v-ErbB, v-Kit or v-Fms results in constitutive activation of receptor tyrosine kinase activity (Roussel et al., 1988; Woolford et al., 1988) . Another mechanism leading to constitutive activation of a receptor tyrosine kinase is exempli®ed by the Val to Glu mutation in the Erb2 transmembrane domain (Bargmann et al., 1986) . While it has been proposed that mutation within the ligand-binding domain or the transmembrane domain somehow stabilizes a conformation equivalent to that induced by ligand binding, data supporting this hypothesis has not directly revealed the molecular mechanism of receptor activation. In the present report, we have utilized a series of Ig-loop deletion mutants of the aPDGFR in order to gain insight into molecular basis for activation of receptor tyrosine kinases (RTKs). Our data demonstrates that deletion of Ig-like loop 3, which is required for PDGF binding, activates the oncogenic potential of this receptor tyrosine kinase by constitutively inducing receptor dimerization. Therefore, our ®ndings provide direct experimental evidence indicating that (1) the biophysical function of ligand binding to PDGFRs may be mimicked by deletion of Ig-like loop 3; (2) ligand binding can be uncoupled from receptor dimerization and activation; and (3) dimerization of PDGFRs must be tightly linked to receptor activation.
Together, all of these results provide a molecular basis for receptor activation by PDGF which is depicted in Figure 6 . According to this model the Iglike domain 3, unlike domain 2 or 1 of the aPDGFR, contains determinants which inhibit constitutive dimerization of the aPDGFR in quiescent cells. Indeed, a molecular model of the con®guration of the extracellular domains 2 and 3 aPDGFR (ECD2-3) built on the three dimensional structure of domain 1 ± 2 of the T cell receptor (CD4) shows that the major PDGF binding cleft of the aPDGFR is highly acidic and located within the CDR 1, 2 and 3 of ECD 3 (data not shown). Therefore, it would be attractive to propose that in the absence of any ligand, the Ig-like domain 3 may stabilize the PDGFRs in a monomeric configuration possibly through electrostatic repulsion between negatively charged residues. Based upon this model, PDGF binding to this region would in turn stimulate receptor dimerization by neutralizing the inhibitory eect of negatively charged residues within this domain. Interestingly, Yarden and coworkers through a series of elegant studies have shown that the Ig-like domain 4 of the c-Kit contains determinants required for receptor dimerization and activation but not for ligand binding (Blechman et al., 1995) . Since the receptor for the Kit ligand is structurally related to aPDGFR and domain 4 of the aPDGFR has also been previously shown not to be involved in ligand binding (Yu et al., 1994) , it is reasonable to propose that the ligand-induced dimerization by PDGF may occur as a multi-step process requiring not only ligand-mediated neutralization of the inhibitory region but also the presence of allosteric changes in extracellular domain 4 of the aPDGFR. Further analysis of the role of extracellular domain 4 of the aPDGFR in receptor dimerization will be needed to test this hypothesis.
Materials and methods

Materials
Recombinant PDGF-AA and PDGF-BB were obtained from Upstate Biotechnology Inc. (Lake Placid, NY). Anti-P-Tyr, a monoclonal antibody generated against phosphotyrosines, was obtained from Biotechnology Inc. Anti-a-PDGFR1 antibody was generated against a peptide encompassing residues 959 ± 973 of the human aPDGFR (Matsui et al., 1989a) . Mab-aR1 is a monoclonal antibody which recognizes human but not the murine aPDGFR in intact cells (LaRochelle et al., 1993) . NIH3T3 mouse ®broblast cells transfected by the standard calcium phosphate precipitation method (Graham and Eb, 1973) .
Cross linking analysis
NIH3T3 cells transfected with vector alone (LTR2) or aR D235 ± 290 were incubated in serum free medium for 2 h. The NIH3T3 transfectants were untreated or treated with PDGF-AA (100 ng/ml) for 3 h at 48C, washed with HEPES/Saline solution (10 mM Hepes, 150 mM NaCl) and treated with 1 mM BS 3 for 20 min at 48C. Following termination of cross-linking experiments, cells are lysed in the lysis buer (50 mM Hepes, pH 7.5, Triton X-100, 50 mM NaCl, 5 mM EDTA, 50 mM NaF, 10 mM Na 4 P 2 O 7 , 1 mM NaVO 4 , 10 mg/ml Aprotinin, 10 mg/ml Leupeptin and 1 mM phenylmethylsulfonyl¯oride), total cell lysates (2 mg) were immunoprecipitated with anti-P-Tyr antibody. The immune complexes were washed extensively in lysis buer, denatured using an equal volume of 26SDS sample buer, and electrophoretically separated by a 4% SDS ± PAGE. The crosslinked species were transferred to immobilon-P and immunoblotted with anti-aPDGFR1 serum.
In vitro kinase assay, immunoblot and immunoprecipitation analyses
For in vitro kinase assays, NIH3T3 transfectants were rendered quiescent and lysed in lysis buer. Total cell lysates (2 mg) were immunoprecipitated with Mab-aR1. Immunecomplexes were washed extensively in lysis buer and incubated in the 10 mM Tris pH=7.5, 10 mM MgCl 2 , 5 mM MnCl 2 , 10 mg/ml Aprotinin, 20 mCi [g-32 P]-ATP (Amersham, Arlington Heights IL) for 15 min at 258C. After removing the free [g-32 P]-ATP, the pellet was denatured in SDS sample buer, and separated by a 7.5% SDS ± PAGE. The gel was dried and autoradiographed. Immunoblotting, immunoprecipitation analysis and focus formation assay were essentially performed as described previously (Heidaran et al., 1990a) .
